Study of the SARS-COV-2 (COVID-19) Serological Profile of an Army Training Hospital Staff
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Sars-CoV2
- Sponsor
- Direction Centrale du Service de Santé des Armées
- Enrollment
- 845
- Locations
- 2
- Primary Endpoint
- Anti-SARS-Cov2 seroconversion between Day 0 and Day 60.
- Status
- Completed
- Last Updated
- 5 years ago
Overview
Brief Summary
Emerging in China in December 2019, Covid-19, whose pathogen is SARS-Cov-2, was declared a global pandemic in March 2020. The clinical presentation is highly variable, ranging from asymptomatic forms to acute respiratory distress and even death. Transmission occurs through droplets, with a R0 of approximately 3.
Rapidly, population protection measures were put in place by governments, including the confinement of all persons whose functions were not considered essential and the closure of educational institutions.
Health care institutions are places at risk of Covid-19 transmission and hospital staff are particularly exposed, either through direct contact with patients, contact with exposed persons or through the environment. In order to protect personnel, hygiene measures were immediately recalled and reinforced.
This study is aimed at evaluating the incidence rate of anti-SARS-Cov2 seroconversion over 2 months among hospital staff, without any supposed anti-Covid treatment 19.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Army Training Hospital staff
Exclusion Criteria
- •Individuals who have already been confirmed Covid-19 positive
- •Individuals taking preventive anti-Covid-19 therapy or considering participating in anti-Covid-19 therapy study
- •Individuals on hydroxychloroquine
- •Pregnant or breastfeeding women
- •Non-permanent staff during the study period
- •Individuals identified for a detachment outside the metropole during the study period
Outcomes
Primary Outcomes
Anti-SARS-Cov2 seroconversion between Day 0 and Day 60.
Time Frame: From Day 0 to Day 60
Change of Anti-SARS-Cov2 serological status between Day 0 and Day 60, measured in blood sample.
Anti-SARS-Cov2 seroconversion between Day 0 and Day 30.
Time Frame: From Day 0 to Day 30
Change of Anti-SARS-Cov2 serological status between Day 0 and Day 30, measured in blood sample.
Anti-SARS-Cov2 seroconversion between Day 30 and Day 60.
Time Frame: From Day 30 to Day 60
Change of Anti-SARS-Cov2 serological status between Day 30 and Day 60, measured in blood sample.
Secondary Outcomes
- Anti-SARS-Cov2 seroprevalence at Day 0.(Day 0)
- Correlation between seroconversion and socio-demographic factors - sex(Day 60)
- Correlation between seroconversion and socio-demographic factors - age(Day 60)
- Correlation between seroconversion and professional factors - job type(Day 60)
- Correlation between seroconversion and professional factors - personal protective equipment type(Day 60)
- Correlation between seroconversion and non-professional factors - contact with infected individuals(Day 60)
- Correlation between seroconversion and non-professional factors - wearing of professional equipment(Day 60)
- Correlation between seroconversion and non-professional factors - respect of barrier gestures(Day 60)